- Previous Close
8.50 - Open
8.53 - Bid 8.51 x 100
- Ask 10.22 x 100
- Day's Range
8.53 - 9.00 - 52 Week Range
6.71 - 17.00 - Volume
807 - Avg. Volume
322,382 - Market Cap (intraday)
394.165M - Beta (5Y Monthly) --
- PE Ratio (TTM)
112.50 - EPS (TTM)
0.08 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.67
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
www.mazetx.comRecent News: MAZE
View MorePerformance Overview: MAZE
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAZE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAZE
View MoreValuation Measures
Market Cap
372.27M
Enterprise Value
202.08M
Trailing P/E
109.28
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.22
Price/Book (mrq)
--
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
3.32
Financial Highlights
Profitability and Income Statement
Profit Margin
31.18%
Return on Assets (ttm)
23.07%
Return on Equity (ttm)
50.48%
Revenue (ttm)
167.5M
Net Income Avi to Common (ttm)
3.4M
Diluted EPS (ttm)
0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
196.81M
Total Debt/Equity (mrq)
13.52%
Levered Free Cash Flow (ttm)
52.09M